Mainz, September 11, 2018 – TRON is thrilled to announce a review co-authored by Ugur Sahin in the journal Nature Reviews Drug Discovery. This article gives an over view of nascent RNA immunotherapeutics, including RNA vaccines encoding cancer neoantigens, mRNAs encoding immunomodulatory factors, viral RNA analogues, interference RNAs and protein-binding RNA aptamers. These approaches
Mainz, May 3, 2018 – The University Medical Center Frankfurt at Goethe University is hosting a seminar in the German Society for Immunology’s Translational Immunology Seminar Series. TRON’s Mustafa Diken will give a lecture titled “mRNA as a versatile platform for cancer vaccines” today at 3:00 p.m. in lecture hall B15 of Building 32 (entrance
Mainz, March 16, 2018 – The Dutch Society for Immunology (NVVI) is hosting the 4th Chemical Immunology Conference today in Amsterdam. The meeting aims to cover the broad diversity of chemical immunology and some of the most exciting areas of research to have emerged. TRON’s Mustafa Diken kicks off the day with his plenary, “mRNA
Mainz, January 29, 2018 – The K. G. Jebsen Center for Cancer Immunotherapy is holding a mini-symposium on The Next Generation of Cancer Immunotherapy. In this context, on February 2 Prof. Ugur Sahin will give a lecture on Personalized Mutanome Vaccines.
Mainz, November 24, 2017 – The University Clinic of Goethe University in Frankfurt is hosting a seminar as part of the German Society for Immunology’s Translational Immunology series. In this context, Sebastian Kreiter will be speaking on “Neo-antigen vaccination in cancer – translating science into survival.” Dr. Kreiter’s presentation will take place on Thursday, 30.
Mainz, October 27, 2017 – EMBL’s Cancer Genomics Conference offers a fabulous opportunity to keep up to date with the rapidly progressing area of cancer genomics. Presentations cover the latest from cancer genome projects, cancer functional genomics, systems biology, cancer immunogenomics and epigenomics, cancer mouse models and the translation and clinical impact of scientific results.
Was versprechen neuartige personalisierte Krebsimmuntherapien? Wie können Patienten von Ihnen profitieren, und welche Risiken bergen die Behandlungen? Zwei neue Ansätze in der Krebsimmuntherapie sind die CAR-T-Methode und die so genannten Neoantigen-Vakzine. Beide werden gerade getestet und sind sehr vielversprechend. Der regionale Radiosender SWR2 sendete hierzu einen Radiobeitrag in seinem Programm. Einen Mitschnitt sowie ein Transkript
The 12th Mainz Clinical Pathology Seminar will assemble experts from the basic scientific, clinical, biopharmaceutical and pathological fields to give an overview of the exciting developments in cancer immunotherapies.
Mainz, 20. December 2016 – TRON scientists kick off special issue in Frontiers in Immunology. This is a call for papers to provide an up-to-date overview of current efforts to understand the immunological mechanisms of neoantigen directed T-cell immunity and the attempts to harvest this source of antigens for cancer immunotherapy. Read more about the
Mainz, 23. November 2016 – Wie entstehen Krebszellen? Ist Krebs erblich? Warum ist es so schwer, Krebs zu behandeln/zu heilen und welche neuen Ansätze zur Krebsbehandlung gibt es? Welche Rolle spielt dabei die individualisierte Immuntherapie – und was ist das überhaupt? TRON und BioNTech tragen 11 Fakten über Krebs zu “Wissen im Herzen” bei, eine
Mainz, November 17 – ‘The immune biology of microsatellite instability cancer: Towards a vaccine against HNPCC’, Prof. von Knebel Doeberitz from the Institute of Pathology at the University of Heidelberg will speak in our seminar on Thursday during his visit at TRON.
Mainz, November 10 – ‘Inducing Neoantigens in Therapeutic and Prophylactic Cancer Immunotherapy’, Prof. Eli Gilboa from the Sylvester Comprehensive Cancer Center at the University of Miami will speak in our seminar on Thursday during his visit at TRON.